VivoSeq
Dermatology

Chronic Spontaneous Urticaria

55

Pipeline Programs↗

21

Active Trials↗

35

Companies Involved↗

Chronic Spontaneous Urticaria is a moderately active landscape with 55 programs across 35 companies. The most active players are United BioPharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, UCB. 2 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

36/100

Mech. Concentration

11/100

Completion Rate

73/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

U

United BioPharma

1 program

Phase 1H

Hangzhou Highlightll Pharmaceutical Co., Ltd

1 program

Phase 1UCB logo

UCB

1 program

Phase 1GSK logo

GSK

1 program

Phase 1B

BeOne Medicines

1 program

Phase 1AstraZeneca logo

AstraZeneca

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

38 of 51 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody1020%Protein / enzyme36%

Small molecule leads; the ring shows all 51 classified programs, each share of the total. Modality classified for 97% of 60 pipeline programs.

Analysis

Trial Status

70

clinical trials

Completed30 · 43%
Recruiting9 · 13%
Terminated8 · 11%
Unknown status7 · 10%
Not yet recruiting6 · 9%
Active, not recruiting5 · 7%
Other5 · 7%

Clinical Trials

Trial Activity

70 trials

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Recruiting·AARS Pharmaceuticals, Inc.·Phase 2·NCT06927999·42 enrolled
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
Recruiting·TTaizhou Mabtech Pharmaceutical Co.,Ltd·Phase 3·NCT06365879·392 enrolled
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Recruiting·Pfizer logoPfizer·Phase 2·NCT07219615·200 enrolled
Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria
Recruiting·—·Phase 4·NCT05916937·40 enrolled
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Recruiting·BBlueprint Medicines·Phase 2·NCT06931405·105 enrolled
Interleukin-2 for Refractory Chronic Spontaneous Urticaria
Recruiting·SSecond Xiangya Hospital of Central South University·Phase 2/3·NCT06924762·124 enrolled
Trial of JYB1904 in Chronic Spontaneous Urticaria.
Recruiting·JJemincare·Phase 2·NCT06509334·135 enrolled
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Recruiting·Sanofi logoSanofi·N/A·NCT07316114·400 enrolled
CUPID: Dupilumab in Chronic Spontaneous Urticaria
Recruiting·Regeneron logoRegeneron·Phase 3·NCT04712201·480 enrolled
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Active, not recruiting·CCelldex Therapeutics·Phase 3·NCT06445023·963 enrolled
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
Active, not recruiting·CCelldex Therapeutics·Phase 3·NCT06455202·976 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria
Active, not recruiting·BeiGene logoBeiGene·Phase 1·NCT07005713·34 enrolled
Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
Active, not recruiting·JJasper Therapeutics, Inc.·Phase 1/2·NCT06162728·88 enrolled
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT05513001·696 enrolled
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Not yet recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2/3·NCT07378527·344 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)